Antimicrobial resistance

The Shareholder Commons Announces Withdrawal of Shareholder Proposal after Yum! Brands Commits to Disclose Systemic Costs of Antibiotic Use

Retrieved on: 
Wednesday, March 3, 2021
Articles, Stock market, Antimicrobial resistance, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Shareholder, Sustainability reporting

Paul Rissman, a long-time shareholder of the Company, worked with The Shareholder Commons, a non-profit organization that seeks to shift the paradigm of investor thinking towards a systems-first approach, to submit a shareholder proposal earlier in the year.

Key Points: 
  • Paul Rissman, a long-time shareholder of the Company, worked with The Shareholder Commons, a non-profit organization that seeks to shift the paradigm of investor thinking towards a systems-first approach, to submit a shareholder proposal earlier in the year.
  • Rissman and The Shareholder Commons have now withdrawn their proposal on the same matter in recognition of the agreement.
  • The agreement with The Shareholder Commons requires the Company to:
    incorporate a study of the system-wide costs of antimicrobial resistance (AMR) into its public sustainability reporting.
  • disclose its findings regarding how antibiotic use in animal husbandry threatens global health and well-being, as well as the global economy and diversified shareholder interests.

Antibiotics Market Size Worth $57.99 Billion By 2028 | CAGR: 4.5%: Grand View Research, Inc.

Retrieved on: 
Tuesday, March 2, 2021
Health sciences, Health, Pharmaceuticals policy, Veterinary medicine, Life sciences, Antibiotic resistance, Evolutionary biology, Antibiotics, Antibiotic use in livestock, Antimicrobial resistance

SAN FRANCISCO, March 2, 2021 /PRNewswire/ -- The global antibiotics market size is expected to reach USD 57.99 billion by 2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, March 2, 2021 /PRNewswire/ -- The global antibiotics market size is expected to reach USD 57.99 billion by 2028, according to a new report by Grand View Research, Inc.
  • High usage of antibiotics and inappropriate prescription behavior of antibiotic drugs worldwide are the major factors anticipated to drive the market.
  • Betterment in the approval process of antibiotic drugs is expected to boost the market growth over the forecast period.
  • Grand View Research has segmented the global antibiotics market on the basis of action mechanism, drug class, and region:
    Antibiotics Action Mechanism Outlook (Revenue, USD Million, 2017 - 2028)

Antibiotics Market Size Worth $57.99 Billion By 2028 | CAGR: 4.5%: Grand View Research, Inc.

Retrieved on: 
Tuesday, March 2, 2021
Health sciences, Health, Pharmaceuticals policy, Veterinary medicine, Life sciences, Antibiotic resistance, Evolutionary biology, Antibiotics, Antibiotic use in livestock, Antimicrobial resistance

SAN FRANCISCO, March 2, 2021 /PRNewswire/ -- The global antibiotics market size is expected to reach USD 57.99 billion by 2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, March 2, 2021 /PRNewswire/ -- The global antibiotics market size is expected to reach USD 57.99 billion by 2028, according to a new report by Grand View Research, Inc.
  • High usage of antibiotics and inappropriate prescription behavior of antibiotic drugs worldwide are the major factors anticipated to drive the market.
  • Betterment in the approval process of antibiotic drugs is expected to boost the market growth over the forecast period.
  • Grand View Research has segmented the global antibiotics market on the basis of action mechanism, drug class, and region:
    Antibiotics Action Mechanism Outlook (Revenue, USD Million, 2017 - 2028)

Staphylococcus aureus, Escherichia coli, and Klebsiella Pneumonia Species to Dominate Antibiotic Resistance Market through 2031 - Persistence Market Research

Retrieved on: 
Wednesday, February 24, 2021
Articles, Health sciences, Health, Pharmaceuticals policy, Veterinary medicine, Antibiotic resistance, Evolutionary biology, Enterobacteriaceae, Antimicrobial resistance, Carbapenem, Antibiotic, Klebsiella pneumoniae

Human overuse of antibiotics leads to the development of antibiotic resistance , which, in turn, demands newer antibiotics.

Key Points: 
  • Human overuse of antibiotics leads to the development of antibiotic resistance , which, in turn, demands newer antibiotics.
  • Escherichia coli and Klebsiella pneumonia are highly resistant to the class of antibiotics called Carbapenem.
  • Antibiotic usage in overwhelming in these countries, leading to increased rates of antibiotic resistance, expected to expand at CAGRs above 5% through 2031.
  • Novartis partnered with over 20 prominent pharmaceutical companies to tackle antibiotic resistance by contributing to the Antimicrobial Resistance (AMR) Action Fund.

Staphylococcus aureus, Escherichia coli, and Klebsiella Pneumonia Species to Dominate Antibiotic Resistance Market through 2031 - Persistence Market Research

Retrieved on: 
Wednesday, February 24, 2021
Articles, Health sciences, Health, Pharmaceuticals policy, Veterinary medicine, Antibiotic resistance, Evolutionary biology, Enterobacteriaceae, Antimicrobial resistance, Carbapenem, Antibiotic, Klebsiella pneumoniae

Human overuse of antibiotics leads to the development of antibiotic resistance , which, in turn, demands newer antibiotics.

Key Points: 
  • Human overuse of antibiotics leads to the development of antibiotic resistance , which, in turn, demands newer antibiotics.
  • Escherichia coli and Klebsiella pneumonia are highly resistant to the class of antibiotics called Carbapenem.
  • Antibiotic usage in overwhelming in these countries, leading to increased rates of antibiotic resistance, expected to expand at CAGRs above 5% through 2031.
  • Novartis partnered with over 20 prominent pharmaceutical companies to tackle antibiotic resistance by contributing to the Antimicrobial Resistance (AMR) Action Fund.

Study Highlights Potential Clinical Value of ePlex® Blood Culture ID Panels

Retrieved on: 
Tuesday, February 16, 2021
Medicine, Sepsis, Clinical medicine, Branches of biology, Bacterial diseases, Blood culture, Bloodstream infections, Fungemia, Antimicrobial resistance

The study, Evaluation of Microbiological Performance and the Potential Clinical Impact of the ePlex Blood Culture Identification Panels for the Rapid Diagnosis of Bacteremia and Fungemia, looked prospectively at the identification of pathogens and antimicrobial resistance genes, as well as retrospectively analyzing clinical outcomes, based on ePlex BCID Panel results compared to standard of care.

Key Points: 
  • The study, Evaluation of Microbiological Performance and the Potential Clinical Impact of the ePlex Blood Culture Identification Panels for the Rapid Diagnosis of Bacteremia and Fungemia, looked prospectively at the identification of pathogens and antimicrobial resistance genes, as well as retrospectively analyzing clinical outcomes, based on ePlex BCID Panel results compared to standard of care.
  • In an analysis of 158 bloodstream infection episodes, the ePlex Blood Culture Identification Panels were utilized to assess potential therapeutic interventions in a timelier manner compared to conventional microbiology.
  • With an overall sensitivity of 98%, the rapid result from the ePlex BCID Panels would have allowed the clinical team to modify treatment in 45% of patients.
  • Moreover, lack of an ePlex BCID result was considered a loss or a probable loss of opportunity for modification of therapy in 28% of patients.

Europe Antibiotics Market Report 2021: Focus on Cephalosporin, Penicillin, Fluoroquinolone, Macrolides, Carbapenem, Aminoglycosides, & Sulfonamides - Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 16, 2021
Health, Pharmaceutical, Health sciences, Health, Articles, Antibiotic resistance, Pharmaceuticals policy, Veterinary medicine, Antibiotic, Evolutionary biology, Pharmacy, Antimicrobial resistance, Infectious Diseases Society of America

The "Europe Antibiotics Market By Action Mechanism, By Drug Class, By Country, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Antibiotics Market By Action Mechanism, By Drug Class, By Country, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.
  • Moreover, favorable government regulations like the Generating Antibiotics Incentives Now (GAIN) Act are estimated to speed up the approval process.
  • The rising numbers of patients who are suffering from infectious diseases lead to the growth of the antibiotics market.
  • The market research report covers the analysis of key stake holders of the market.

North America Antibiotics Market Report 2021: Action Mechanism, Drug Class, Country, Industry Analysis and Forecast, 2020 - 2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 16, 2021
Health, Pharmaceutical, Branches of biology, Health sciences, Health, Hepatotoxins, Penicillins, Antibiotic, Antimicrobial resistance, Antibiotic use in livestock

The "North America Antibiotics Market By Action Mechanism, By Drug Class, By Country, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Antibiotics Market By Action Mechanism, By Drug Class, By Country, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.
  • With the discovery of the antibiotic penicillin in 1920, many antibiotic compounds have been utilized to cure various bacterial infections.
  • The development of unique approaches for advanced antibiotics for curing bacterial infections and numerous clinical trials drives the global antibiotics market.
  • Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

Recce Pharmaceuticals Announces Agreement with Fiona Stanley Hospital for a Phase 1/2 Clinical Trial Evaluating Topical Spray-On Antibiotic RECCE® 327 on Chronic Burn Wounds

Retrieved on: 
Tuesday, February 16, 2021
Articles, Health sciences, Pharmaceuticals policy, Antimicrobial resistance, Evolutionary biology, Veterinary medicine, Burn, Health

Our team is keen to identify and add new treatments with the potential to overcome antibiotic resistance and improve patients lives.

Key Points: 
  • Our team is keen to identify and add new treatments with the potential to overcome antibiotic resistance and improve patients lives.
  • The Phase 1/2 topical study will enroll up to 30 patients and be conducted at Fiona Stanley Hospital Burns Unit in Perth Western Australia.
  • Over 14 days, 10 patients will receive RECCE 327 daily, while 20 patients will receive treatment three times per week.
  • Burn wound specialists will oversee delivery of RECCE 327 in a spray-on formulation, specifically developed for the study.

EU-JAMRAI urges governments and stakeholders to find a sustainable commitment to fight Antimicrobial Resistance

Retrieved on: 
Friday, February 12, 2021
Articles, Pharmaceuticals policy, Health sciences, Antimicrobial resistance, Evolutionary biology, Veterinary medicine, Sarah Wiener, Antimicrobial, Life sciences

MADRID, Feb. 12, 2021 /PRNewswire/ -- We are handing over the beginning rather than the end in the fight against Antimicrobial Resistance (AMR).

Key Points: 
  • MADRID, Feb. 12, 2021 /PRNewswire/ -- We are handing over the beginning rather than the end in the fight against Antimicrobial Resistance (AMR).
  • Participants urged the European Commission, governments and stakeholders to demonstrate a sustainable commitment to tackle this global threat to public health.
  • Some keynote speakers were Charles Price, DG Sant (European Commission); Danilo Lo Fo Wong, Programme Manager, Antimicrobial Resistance (World Health Organization); or Sarah Wiener, Chair of MEP Interested Group on AMR.
  • 2Practical, evidence-based approach which prevents patients and health workers from being harmed by avoidable infection and as a result of antimicrobial resistance (source: WHO).